CA3088998A1 - Quinolone analogs and their salts, compositions, and method for their use - Google Patents
Quinolone analogs and their salts, compositions, and method for their use Download PDFInfo
- Publication number
- CA3088998A1 CA3088998A1 CA3088998A CA3088998A CA3088998A1 CA 3088998 A1 CA3088998 A1 CA 3088998A1 CA 3088998 A CA3088998 A CA 3088998A CA 3088998 A CA3088998 A CA 3088998A CA 3088998 A1 CA3088998 A1 CA 3088998A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- compound
- pharmaceutical composition
- stored
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631174P | 2018-02-15 | 2018-02-15 | |
| US201862631171P | 2018-02-15 | 2018-02-15 | |
| US62/631,171 | 2018-02-15 | ||
| US62/631,174 | 2018-02-15 | ||
| PCT/US2019/018225 WO2019168688A2 (en) | 2018-02-15 | 2019-02-15 | Quinolone analogs and their salts, compositions, and method for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3088998A1 true CA3088998A1 (en) | 2019-09-06 |
Family
ID=67805108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3088998A Pending CA3088998A1 (en) | 2018-02-15 | 2019-02-15 | Quinolone analogs and their salts, compositions, and method for their use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190374550A1 (https=) |
| EP (1) | EP3752149A4 (https=) |
| JP (1) | JP7445597B2 (https=) |
| KR (1) | KR102914215B1 (https=) |
| CN (1) | CN112334133A (https=) |
| AU (1) | AU2019227294B2 (https=) |
| CA (1) | CA3088998A1 (https=) |
| IL (1) | IL276513A (https=) |
| RU (1) | RU2020130050A (https=) |
| TW (1) | TWI884912B (https=) |
| WO (1) | WO2019168688A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7017509B2 (ja) | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| CN112334133A (zh) | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
| CA3151116A1 (en) * | 2019-08-14 | 2021-02-18 | Hshiou-Ting Liu | Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use |
| EP4013421A4 (en) * | 2019-08-14 | 2023-08-23 | Senhwa Biosciences, Inc. | TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE |
| US20220062294A1 (en) * | 2020-09-02 | 2022-03-03 | Senhwa Biosciences, Inc. | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts |
| WO2023059148A1 (ko) * | 2021-10-08 | 2023-04-13 | 기초과학연구원 | 항암 치료 개선을 위한 2-클로로-n,n-디에틸에틸아민 염산염의 용도 |
| CN118005653B (zh) * | 2023-04-23 | 2024-12-10 | 信义核新(北京)生物科技有限公司 | 喹诺酮类似物及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1165508B1 (en) | 1999-04-07 | 2004-06-23 | The University of Virginia Patent Foundation | Anticancer calcium channel blockers |
| JP2005511743A (ja) | 2001-12-13 | 2005-04-28 | ウォックハート・リミテッド | 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用 |
| US6900224B2 (en) | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| US20050118291A1 (en) | 2003-09-10 | 2005-06-02 | Mian-Ying Wang | Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane |
| WO2005033108A1 (en) | 2003-09-22 | 2005-04-14 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| PL2305221T3 (pl) | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2006034113A2 (en) | 2004-09-17 | 2006-03-30 | Cylene Pharmaceuticals, Inc. | Quinolone analogs as cell proliferation inhibitors |
| US7816524B2 (en) | 2005-08-05 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Methods of preparing quinolone analogs |
| JP2009504192A (ja) | 2005-08-19 | 2009-02-05 | サイリーン ファーマシューティカルズ インコーポレーティッド | ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 |
| AR057555A1 (es) | 2005-10-27 | 2007-12-05 | Merck Frosst Canada Ltd | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo |
| US20090291437A1 (en) * | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
| EP2023720A4 (en) | 2006-05-17 | 2009-06-10 | Cylene Pharmaceuticals Inc | TETRACYCLIC IMIDAZOLE ANALOG |
| WO2007146813A2 (en) | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Pyridinone analogs as cell proliferation inhibitors |
| WO2007146831A2 (en) | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US20110065687A1 (en) | 2007-04-17 | 2011-03-17 | Michael Schwaebe | Hydrazide compounds and uses thereof |
| US7928100B2 (en) | 2007-10-05 | 2011-04-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| AU2008201871A1 (en) | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| US9359605B2 (en) | 2011-03-11 | 2016-06-07 | Sarissa Inc. | Method of treating cancer by inhibition of DNA repair proteins |
| US20140086839A1 (en) * | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| WO2013133876A1 (en) | 2011-12-07 | 2013-09-12 | The Regents Of The University Of California | Biomarkers for prediction of response to parp inhibition in breast cancer |
| US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| ES2754207T3 (es) * | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
| KR102410090B1 (ko) | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| JP7017509B2 (ja) | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| JP2018537486A (ja) * | 2015-12-14 | 2018-12-20 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びその塩の結晶形 |
| US9957282B2 (en) * | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| WO2017100925A1 (en) | 2015-12-15 | 2017-06-22 | British Columbia Cancer Agency Branch | Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof |
| WO2017205832A1 (en) * | 2016-05-26 | 2017-11-30 | Fred Hutchinson Cancer Research Center | L-myc pathway targeting as a treatment for small cell lung cancer |
| CN112334133A (zh) | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
| EP4013421A4 (en) | 2019-08-14 | 2023-08-23 | Senhwa Biosciences, Inc. | TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE |
| CA3151116A1 (en) | 2019-08-14 | 2021-02-18 | Hshiou-Ting Liu | Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use |
| US20220062294A1 (en) | 2020-09-02 | 2022-03-03 | Senhwa Biosciences, Inc. | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts |
-
2019
- 2019-02-15 CN CN201980024456.2A patent/CN112334133A/zh active Pending
- 2019-02-15 KR KR1020207026675A patent/KR102914215B1/ko active Active
- 2019-02-15 EP EP19761078.5A patent/EP3752149A4/en active Pending
- 2019-02-15 JP JP2020543634A patent/JP7445597B2/ja active Active
- 2019-02-15 AU AU2019227294A patent/AU2019227294B2/en active Active
- 2019-02-15 US US16/277,089 patent/US20190374550A1/en not_active Abandoned
- 2019-02-15 CA CA3088998A patent/CA3088998A1/en active Pending
- 2019-02-15 TW TW108105212A patent/TWI884912B/zh active
- 2019-02-15 RU RU2020130050A patent/RU2020130050A/ru unknown
- 2019-02-15 WO PCT/US2019/018225 patent/WO2019168688A2/en not_active Ceased
-
2020
- 2020-08-05 IL IL276513A patent/IL276513A/en unknown
-
2021
- 2021-08-05 US US17/394,541 patent/US11524012B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019168688A3 (en) | 2019-10-10 |
| WO2019168688A2 (en) | 2019-09-06 |
| RU2020130050A (ru) | 2022-03-15 |
| IL276513A (en) | 2020-09-30 |
| EP3752149A2 (en) | 2020-12-23 |
| KR20200131251A (ko) | 2020-11-23 |
| EP3752149A4 (en) | 2022-03-02 |
| JP2021513986A (ja) | 2021-06-03 |
| TW202000195A (zh) | 2020-01-01 |
| CN112334133A (zh) | 2021-02-05 |
| KR102914215B1 (ko) | 2026-01-20 |
| TWI884912B (zh) | 2025-06-01 |
| US20190374550A1 (en) | 2019-12-12 |
| JP7445597B2 (ja) | 2024-03-07 |
| WO2019168688A9 (en) | 2019-11-14 |
| AU2019227294B2 (en) | 2023-06-15 |
| US11524012B1 (en) | 2022-12-13 |
| AU2019227294A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11524012B1 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
| JP6763919B2 (ja) | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 | |
| US20210332071A1 (en) | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | |
| CN109819649B (zh) | 氨基嘌呤化合物的固体形式及其使用方法 | |
| TW201534305A (zh) | 使用組合療法治療癌症之方法 | |
| JP6147246B2 (ja) | Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法 | |
| US20250282752A1 (en) | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | |
| AU2020328590B2 (en) | Tetracyclic compounds and their salts, compositions, and methods for their use | |
| US20220062294A1 (en) | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts | |
| US20210046082A1 (en) | Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use | |
| US20140275234A1 (en) | Compositions and methods of using crystalline forms of wortmannin analogs | |
| HK40052182B (zh) | 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途 | |
| HK1193754A (en) | Combinations of akt and mek inhibitor compounds, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240801 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250401 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250704 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250704 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250704 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250721 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |